IDEXX Laboratories 将来の成長

Future 基準チェック /36

IDEXX Laboratories利益と収益がそれぞれ年間9.8%と7.6%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に34.2% 10.8%なると予測されています。

主要情報

9.8%

収益成長率

10.8%

EPS成長率

Medical Equipment 収益成長	0%
収益成長率	7.6%
将来の株主資本利益率	34.2%
アナリストカバレッジ	Good
最終更新日	15 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BMV:IDXX * - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	4,532	1,103	1,067	1,224	9
12/31/2025	4,161	984	988	1,120	11
12/31/2024	3,882	875	867	1,133	9
9/30/2024	3,845	866	793	917	N/A
6/30/2024	3,785	846	839	969	N/A
3/31/2024	3,725	867	797	921	N/A
12/31/2023	3,661	845	773	907	N/A
9/30/2023	3,588	823	680	830	N/A
6/30/2023	3,514	791	593	747	N/A
3/31/2023	3,431	699	456	612	N/A
12/31/2022	3,367	679	384	543	N/A
9/30/2022	3,340	670	438	580	N/A
6/30/2022	3,309	664	429	578	N/A
3/31/2022	3,274	735	605	746	N/A
12/31/2021	3,215	745	636	756	N/A
9/30/2021	3,135	757	663	765	N/A
6/30/2021	3,047	728	694	770	N/A
3/31/2021	2,858	674	666	745	N/A
12/31/2020	2,707	582	540	648	N/A
9/30/2020	2,591	497	445	585	N/A
6/30/2020	2,475	460	366	524	N/A
3/31/2020	2,457	437	286	453	N/A
12/31/2019	2,407	428	304	459	N/A
9/30/2019	2,351	423	290	439	N/A
6/30/2019	2,291	407	274	418	N/A
3/31/2019	2,252	390	262	400	N/A
12/31/2018	2,213	377	277	400	N/A
9/30/2018	2,170	330	280	386	N/A
6/30/2018	2,117	307	N/A	386	N/A
3/31/2018	2,045	284	N/A	377	N/A
12/31/2017	1,969	263	N/A	373	N/A
9/30/2017	1,906	277	N/A	353	N/A
6/30/2017	1,862	263	N/A	343	N/A
3/31/2017	1,820	245	N/A	343	N/A
12/31/2016	1,775	222	N/A	339	N/A
9/30/2016	1,732	214	N/A	312	N/A
6/30/2016	1,690	202	N/A	289	N/A
3/31/2016	1,637	192	N/A	258	N/A
12/31/2015	1,602	192	N/A	222	N/A
9/30/2015	1,554	174	N/A	170	N/A
6/30/2015	1,531	182	N/A	186	N/A
3/31/2015	1,508	182	N/A	188	N/A
12/31/2014	1,486	182	N/A	236	N/A
9/30/2014	1,488	199	N/A	274	N/A
6/30/2014	1,443	193	N/A	259	N/A
3/31/2014	1,405	190	N/A	258	N/A
12/31/2013	1,377	188	N/A	246	N/A

アナリストによる今後の成長予測

収入対貯蓄率: IDXX *の予測収益成長率 (年間9.8% ) は貯蓄率 ( 8.1% ) を上回っています。

収益対市場: IDXX *の収益 ( 9.8% ) MX市場 ( 11.4% ) よりも低い成長が予測されています。

高成長収益: IDXX *の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: IDXX *の収益 ( 7.6% ) MX市場 ( 7.2% ) よりも速いペースで成長すると予測されています。

高い収益成長: IDXX *の収益 ( 7.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: IDXX *の自己資本利益率は、3年後には高くなると予測されています ( 34.2 %)

IDEXX Laboratories 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

IDEXX Laboratories, Inc. Revises Earnings Guidance for the Year 2024

Idexx Laboratories, Inc. Revises Earnings Guidance for 2024

IDEXX Laboratories, Inc. Provides Financial Guidance for 2024

IDEXX Laboratories, Inc. Provides Financial Guidance for 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Fiscal Year 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2023

Recent updates

IDEXX Laboratories, Inc. Announces Chief Financial Officer Changes

Third quarter 2024 earnings released: EPS: US$2.83 (vs US$2.55 in 3Q 2023)

Independent Director recently sold Mex$4.7m worth of stock

IDEXX Laboratories, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: EPS: US$2.46 (vs US$2.70 in 2Q 2023)

IDEXX Laboratories, Inc. Revises Earnings Guidance for the Year 2024

Independent Director recently sold Mex$1.8m worth of stock

IDEXX Laboratories, Inc. to Report Q2, 2024 Results on Aug 06, 2024

IDEXX Laboratories, Inc., Annual General Meeting, May 06, 2024

First quarter 2024 earnings released: EPS: US$2.84 (vs US$2.58 in 1Q 2023)

Idexx Laboratories, Inc. Revises Earnings Guidance for 2024

Insufficient new directors

Idexx Launches Vellotm, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect

IDEXX Laboratories, Inc. to Report Q1, 2024 Results on May 02, 2024

IDEXX Laboratories, Inc. Provides Financial Guidance for 2024

Full year 2023 earnings released: EPS: US$10.17 (vs US$8.12 in FY 2022)

Insufficient new directors

IDEXX Laboratories, Inc. Announces Retirement of James F. Polewaczyk, Executive Vice President and Chief Commercial Officer, Effective April 1, 2024

Insufficient new directors

IDEXX Laboratories, Inc. Expands Snap Platform with Leish 4Dx Test to Support Veterinarians Globally in Diagnosing Vector-Borne Diseases

IDEXX Laboratories, Inc. Provides Financial Guidance for 2023

Third quarter 2023 earnings released: EPS: US$2.55 (vs US$2.17 in 3Q 2022)

IDEXX Laboratories, Inc. to Report Q4, 2023 Results on Feb 05, 2024

Executive VP & Chief Commercial Officer recently sold Mex$52m worth of stock

IDEXX Laboratories, Inc. to Report Q3, 2023 Results on Nov 01, 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Insufficient new directors

IDEXX Laboratories, Inc. Announces the Election of Irene Chang Britt as an Independent Class I Director and as an Independent Member of Audit Committee and Compensation and Talent Committee

Insufficient new directors

IDEXX Laboratories, Inc. Announces Novel Diagnostic Test for Kidney Injury, Expanding the Veterinary Industry's Most Comprehensive Renal Testing Portfolio

Insufficient new directors

Independent Director recently sold Mex$17m worth of stock

First quarter 2023 earnings released: EPS: US$2.58 (vs US$2.30 in 1Q 2022)

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

IDEXX Laboratories, Inc. to Report Q1, 2023 Results on May 02, 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2023

Insufficient new directors

Insufficient new directors

IDEXX Laboratories, Inc. to Report Q4, 2022 Results on Feb 06, 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2022

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Year 2022

Investor sentiment deteriorated over the past week

IDEXX Laboratories, Inc. to Report Q2, 2022 Results on Aug 02, 2022

First quarter 2022 earnings released: EPS: US$2.30 (vs US$2.39 in 1Q 2021)

IDEXX Laboratories, Inc., Annual General Meeting, May 11, 2022

IDEXX Laboratories, Inc. to Report Q1, 2022 Results on May 04, 2022

Senior Advisor & Director recently sold Mex$2.6m worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Year 2022

IDEXX Laboratories, Inc. Announces Series of Product and Service Enhancements That Enable Veterinary Practices to Be More Efficient While Managing Increasing Patient Volumes

President recently sold Mex$81m worth of stock

Insider recently sold Mex$142m worth of stock

IDEXX Laboratories, Inc.(NasdaqGS:IDXX) dropped from Russell 1000 Dynamic Index

IDEXX Laboratories, Inc. (NasdaqGS:IDXX) acquired ezyVet.

Independent Director has left the company

Senior Advisor & Director recently sold Mex$5.5m worth of stock

First quarter 2021 earnings released: EPS US$2.39 (vs US$1.31 in 1Q 2020)

IDEXX Laboratories, Inc. Raises Earnings Guidance for 2021

Independent Director recently sold Mex$3.3m worth of stock

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘